Abbott Laboratories (NYSE:ABT) Price Target Cut to $140.00 by Analysts at Argus

Abbott Laboratories (NYSE:ABT) had its price target cut by Argus from $150.00 to $140.00 in a research note issued to investors on Tuesday,MarketScreener reports.

ABT has been the subject of several other research reports. Benchmark began coverage on Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 price objective for the company. Jefferies Financial Group increased their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Citigroup dropped their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, Oppenheimer lowered their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $140.75.

Abbott Laboratories Stock Down 2.0%

Shares of ABT stock traded down $2.19 during trading on Tuesday, reaching $106.08. The company’s stock had a trading volume of 7,178,747 shares, compared to its average volume of 10,923,620. Abbott Laboratories has a 1-year low of $105.78 and a 1-year high of $141.23. The stock’s 50-day moving average price is $123.90 and its 200 day moving average price is $127.95. The company has a market capitalization of $184.46 billion, a price-to-earnings ratio of 28.50, a P/E/G ratio of 1.73 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is 67.74%.

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds have recently made changes to their positions in ABT. Kanawha Capital Management LLC grew its holdings in shares of Abbott Laboratories by 1.8% in the 4th quarter. Kanawha Capital Management LLC now owns 179,351 shares of the healthcare product maker’s stock worth $22,471,000 after acquiring an additional 3,095 shares during the period. Confluence Wealth Services Inc. grew its holdings in Abbott Laboratories by 0.8% in the fourth quarter. Confluence Wealth Services Inc. now owns 31,780 shares of the healthcare product maker’s stock valued at $3,982,000 after purchasing an additional 254 shares during the last quarter. EPG Wealth Management LLC increased its position in shares of Abbott Laboratories by 1.5% in the fourth quarter. EPG Wealth Management LLC now owns 11,315 shares of the healthcare product maker’s stock valued at $1,418,000 after buying an additional 165 shares in the last quarter. Caprock Group LLC raised its stake in shares of Abbott Laboratories by 5.8% during the 4th quarter. Caprock Group LLC now owns 68,036 shares of the healthcare product maker’s stock worth $8,524,000 after buying an additional 3,706 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC boosted its position in shares of Abbott Laboratories by 14.0% in the 4th quarter. Kingswood Wealth Advisors LLC now owns 11,313 shares of the healthcare product maker’s stock worth $1,418,000 after buying an additional 1,386 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.